All In Biotech

Drug Trial Radar · NCT07185282

A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of MH004 Ointment Followed by a 44-week Open-Label Long-Term Safety Extension Period in Adolescents and Adults With Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

375

Actual

Start

Jun 10, 2023

Primary completion

Dec 13, 2024

Study completion Aug 15, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with mild to moderate atopic dermatitis.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • MH004 OintmentDrug

    MH004 1% ointment applied topically to the affected area as a thin film twice daily.

  • Vehicle OintmentDrug

    Matching vehicle ointment applied topically to the affected area as a thin film twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving Investigator's Global Assessment treatment success (IGA-TS) at Week 4.Time frame: Baseline to week 4.
  2. Proportion of participants achieving EASI-75 at Week 4.Time frame: Baseline to week 4.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.